ARCT

Arcturus Therapeutics Holdings Inc. (ticker: ARCT) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of ARCT's SEC filings surfaces 3 active risk signals, including 2 late-filing signals, and 1 auditor-change signal. ARCT reported $2.06M in revenue and -$26.96M for the period ending 2026-03-31, with operating cash flow of -$19.44M. Cash and equivalents stood at $211.38M (down 2.6% year-over-year). Total assets of $245.41M exceed total liabilities of $54.05M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.